Our website uses cookies to make navigation as functional as possible and to perform statistics on its usage. Should you wish to receive more information, or deny your consent to all or some of the cookies, please click here. By continuing to browse this website, you will be accepting our cookies.
More info
25 Sep 2020
Radius Health & Menarini Group Provide Elacestrant Update
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) and the Menarini Group today announced an update on the elacestrant Phase 3 EMERALD trial.
Read more
17 Sep 2020
Menarini Ricerche Announces Dose Escalation Results of the Clinical Trial of MEN1611 in Breast Cancer
Menarini Ricerche today announced the results of the dose escalation part of its B-PRECISE-01 clinical trial (NCT03767335) which is evaluating MEN1611,
Read more
16 Sep 2020
Menarini Ricerche Announces Initiation of Cohort Expansion for the Clinical Study of SEL24/MEN1703 in Acute Myeloid Leukemia
Menarini Ricerche, the R&D division of the Menarini Group, announced today that it has treated the first patient in Europe for the cohort expansion part of DIAMOND-01 clinical trial
Read more
11 Sep 2020
International Fair Play Menarini award 2020
Read more
01 Sep 2020
ANNOUNCED THE XXIV EDITION OF THE INTERNATIONAL FAIR PLAY MENARINI AWARD
The spotlight is on the  XXIV   International Fair Play Menarini Award , which was officially presented in Rome. The 2020 programme and winners were revealed in the presence of  CONI (The Italian National Olympic Commit...
Read more
23 Jul 2020
Menarini Group and Radius Health Announce Global License Agreement for the Development and Commercialization of Elacestrant
The Menarini Group and Radius Health, Inc. (Nasdaq: RDUS) announced today that the companies have entered into an exclusive global license agreement for development and commercialization of elacestrant. Elacestrant is an ora...
Read more
Page 1 of 5First   Previous   [1]  2  3  4  5  Next   Last